130 related articles for article (PubMed ID: 12003006)
1. Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus.
Hatano K; Morishita Y; Nakai T; Ikeda F
J Antibiot (Tokyo); 2002 Feb; 55(2):219-22. PubMed ID: 12003006
[No Abstract] [Full Text] [Related]
2. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.
Uchida K; Nishiyama Y; Yokota N; Yamaguchi H
J Antibiot (Tokyo); 2000 Oct; 53(10):1175-81. PubMed ID: 11132964
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.
Tawara S; Ikeda F; Maki K; Morishita Y; Otomo K; Teratani N; Goto T; Tomishima M; Ohki H; Yamada A; Kawabata K; Takasugi H; Sakane K; Tanaka H; Matsumoto F; Kuwahara S
Antimicrob Agents Chemother; 2000 Jan; 44(1):57-62. PubMed ID: 10602723
[TBL] [Abstract][Full Text] [Related]
4. Serum differentially alters the antifungal properties of echinocandin drugs.
Paderu P; Garcia-Effron G; Balashov S; Delmas G; Park S; Perlin DS
Antimicrob Agents Chemother; 2007 Jun; 51(6):2253-6. PubMed ID: 17420211
[TBL] [Abstract][Full Text] [Related]
5. WF11899A, B and C, novel antifungal lipopeptides. II. Biological properties.
Iwamoto T; Fujie A; Nitta K; Hashimoto S; Okuhara M; Kohsaka M
J Antibiot (Tokyo); 1994 Oct; 47(10):1092-7. PubMed ID: 7961157
[TBL] [Abstract][Full Text] [Related]
6. Novel echinocandin antifungals. Part 2: Optimization of the side chain of the natural product FR901379. Discovery of micafungin.
Tomishima M; Ohki H; Yamada A; Maki K; Ikeda F
Bioorg Med Chem Lett; 2008 May; 18(9):2886-90. PubMed ID: 18424132
[TBL] [Abstract][Full Text] [Related]
7. Effect of Micafungin (FK463) on Candida albicans adherence to epithelial cells.
Borg-von Zepelin M; Zaschke K; Gross U; Monod M; Müller FM
Chemotherapy; 2002 Jul; 48(3):148-53. PubMed ID: 12138332
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice.
Maesaki S; Hossain MA; Miyazaki Y; Tomono K; Tashiro T; Kohno S
Antimicrob Agents Chemother; 2000 Jun; 44(6):1728-30. PubMed ID: 10817741
[TBL] [Abstract][Full Text] [Related]
9. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
Warn PA; Morrissey G; Morrissey J; Denning DW
J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
[TBL] [Abstract][Full Text] [Related]
10. Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide.
Nishiyama Y; Uchida K; Yamaguchi H
J Electron Microsc (Tokyo); 2002; 51(4):247-55. PubMed ID: 12227555
[TBL] [Abstract][Full Text] [Related]
11. Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability.
Watabe E; Nakai T; Matsumoto S; Ikeda F; Hatano K
Antimicrob Agents Chemother; 2003 Jun; 47(6):1995-8. PubMed ID: 12760883
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis.
Ikeda F; Wakai Y; Matsumoto S; Maki K; Watabe E; Tawara S; Goto T; Watanabe Y; Matsumoto F; Kuwahara S
Antimicrob Agents Chemother; 2000 Mar; 44(3):614-8. PubMed ID: 10681327
[TBL] [Abstract][Full Text] [Related]
13. [New antifungal agents].
Miyazaki Y; Kawano S
Jpn J Antibiot; 2002 Dec; 55(6):911-2. PubMed ID: 12664932
[No Abstract] [Full Text] [Related]
14. [The future of antifungal agents. Non azole antifungal agents].
Maesaki S; Hossain MA; Sasaki E; Hashiguchi K; Higashiyama Y; Yoshitsugu Y; Tomono K; Tashiro T; Kohno S
Nihon Ishinkin Gakkai Zasshi; 1999; 40(3):157-61. PubMed ID: 10423510
[TBL] [Abstract][Full Text] [Related]
15. [Antifungal activity and clinical efficacy of micafungin (funguard)].
Ikeda F
Nihon Ishinkin Gakkai Zasshi; 2005; 46(4):217-22. PubMed ID: 16282962
[TBL] [Abstract][Full Text] [Related]
16. Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis.
Müller FM; Kurzai O; Hacker J; Frosch M; Mühlschlegel F
J Antimicrob Chemother; 2001 Nov; 48(5):713-5. PubMed ID: 11679561
[TBL] [Abstract][Full Text] [Related]
17. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide.
Mikamo H; Sato Y; Tamaya T
J Antimicrob Chemother; 2000 Sep; 46(3):485-7. PubMed ID: 10980180
[TBL] [Abstract][Full Text] [Related]
18. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase.
Kurtz MB; Heath IB; Marrinan J; Dreikorn S; Onishi J; Douglas C
Antimicrob Agents Chemother; 1994 Jul; 38(7):1480-9. PubMed ID: 7979276
[TBL] [Abstract][Full Text] [Related]
19. Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro.
Jacobsen MD; Whyte JA; Odds FC
Antimicrob Agents Chemother; 2007 May; 51(5):1882-4. PubMed ID: 17307974
[TBL] [Abstract][Full Text] [Related]
20. FR227673 and FR190293, novel antifungal lipopeptides from Chalara sp. No. 22210 and tolypocladium parasiticum No. 16616.
Kanasaki R; Kobayashi M; Fujine K; Sato I; Hashimoto M; Takase S; Tsurumi Y; Fujie A; Hino M; Hashimoto S; Hori Y
J Antibiot (Tokyo); 2006 Mar; 59(3):158-67. PubMed ID: 16724456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
